SOURCE: The Reporting Group

October 27, 2014 11:00 ET

Cesca Therapeutics Shareholders Reporting Group File 13D

RANCHO CORDOVA, CA--(Marketwired - Oct 27, 2014) - A Schedule 13D has been filed with the U.S. Securities and Exchange Commission on behalf of a group of shareholders in Cesca Therapeutics, a company formed by the merger earlier this year of leading cell-therapy device-maker ThermoGenesis Corp. and regenerative medicine clinical therapy company TotipotentRX, engaged in the research, development, and commercialization of point-of-care cell-based therapeutics for use in multiple chronic medical illnesses, including critical limb ischemia and acute myocardial infarction.

The group is comprised of seven parties, many of whom had strong ties to TotipotentRX, including leaders of its innovative product development and capital finance teams: Cesca Therapeutics President and Director Kenneth L. Harris, Cesca Therapeutics Chief Biologist Mitchel Sivilotti, EMR Vermoegensverwaltung GmbH, Michael Rhein, AsGe Vermoegensverwaltung GmbH, Gernot Rehra, and Gary R. Cohan, M.D. The group, which owns 11,512,364 shares in Cesca (28.6% of the company's outstanding shares), was formed to better leverage the company's opportunities for vertical integration of cell-therapy-based point-of-care treatments in the commercial cell-therapy market.

Cesca Therapeutics remains committed to optimizing the integration of the two companies since their merger in February 2014, improving capital management, enhancing Cesca's cell-therapy market differentiators and bringing these high-value structural advantages to the bottom line for the benefit of all stockholders. The reporting group supports the appointment of Mr. Michael Rhein, a 30-year veteran and a managing director of Deutsche Bank AG from 1996 to 2012, to serve on the Cesca Board of Directors consistent with the merger agreement.

A focus on prudent capital management, including optimization of its cord blood business is essential for Cesca Therapeutics as it prepares to enter the exciting late stage development of its Critical Limb Ischemia Therapy.

The reporting group looks forward to the annual meeting of shareholders in December 2014.

Ken Harris, President and Director of Cesca Therapeutics and a member of the reporting group, remarks, "Cesca Therapeutics' autologous stem cell-based therapies, research and development programs, medical and diagnostic devices, and cell manufacturing are designed to benefit patients, physicians and the community at large. We look forward to guiding the merged company as Cesca moves forward toward a seamless integration of its multiple platforms, research, development, treatment and marketing arms."

Contact Information

    Devon Blaine
    John Charnay
    The Blaine Group
    310/360-1498 (FAX)
    Email Contact

    The Blaine Group, Inc.
    A Total Communications Agency
    8665 Wilshire Blvd., Suite #301
    Beverly Hills, CA 90211